SCHEMBL12376900

SCHEMBL12376900

CC(C)(C#Cc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)c2s1)N1CCC(CO)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 17/20 0.53
KDR P35968 12/20 0.53
AXL P30530 5/20 0.53
KIT P10721 4/20 0.53
FLT3 P36888 4/20 0.53
NTRK1 P04629 2/20 0.53
NTRK2 Q16620 2/20 0.53
MERTK Q12866 2/20 0.48
RET P07949 3/20 0.47
PDGFRA P16234 2/20 0.47
PDGFRB P09619 2/20 0.46
PLK4 O00444 1/20 0.46
STK25 O00506 1/20 0.46
CIT O14578 1/20 0.46
AURKA O14965 1/20 0.46
CHUK O15111 1/20 0.46
MUSK O15146 1/20 0.46
EPHB6 O15197 1/20 0.46
MAPK13 O15264 1/20 0.46
MAP3K13 O43283 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12376899 0.91 MET (0.55) METKDRAXLKITFLT3
SCHEMBL12376901 0.90 MET (0.56) METKDRAXLKITFLT3
SCHEMBL12376898 0.87 MET (0.52) METKDRAXLKITFLT3
SCHEMBL2278505 0.84 MET (0.36) METKDRAXLKITFLT3
SCHEMBL12410933 0.81 MET (0.53) METKDRAXLKITFLT3
SCHEMBL12376903 0.81 MET (0.52) METKDRAXLKITFLT3
SCHEMBL12376904 0.80 MET (0.54) METKDRAXLKITFLT3
SCHEMBL12376888 0.80 MET (0.56) METKDRAXLKITFLT3
SCHEMBL12376889 0.80 MET (0.58) METKDRAXLKITFLT3
SCHEMBL12376890 0.80 MET (0.53) METKDRAXLKITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 US disclosed
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 US disclosed
WO-2008063202-A2 HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER ARRAY BIOPHARMA INC. (US) 2008-05-29 WO disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC MET 142/4885KDR 419/4885AXL 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.